Christine Chambers is recorded as CFO at Fusemachines Inc. (FUSE) and CFO at Petmed Express Inc (PETS). The newest filing on record that lists Christine Chambers as CFO at Fusemachines Inc. (FUSE) is dated April 27, 2026. The newest filing on record that lists Christine Chambers as CFO at Petmed Express Inc (PETS) is dated June 24, 2024. Fusemachines Inc. reported in an 8-K filed October 29, 2025 that Christine Chambers was appointed Chief Financial Officer, effective July 23, 2025. Petmed Express Inc reported in an 8-K filed August 3, 2022 that Christine Chambers was appointed Chief Financial Officer, effective August 3, 2022. Petmed Express Inc reported in an 8-K filed July 14, 2022 that Christine Chambers was appointed Chief Financial Officer, effective August 3, 2022. The proxy statement of Petmed Express Inc reports total compensation of $521,361 for Christine Chambers in fiscal 2025, including a base salary of $155,769. Disclosed compensation is on record for 5 fiscal years. Christine Chambers has spoken on 9 earnings calls across 1 company, most recently for Petmed Express Inc on August 6, 2024. Petmed Express Inc is classified in the Pharmaceutical Retailers industry within the Healthcare sector. Fusemachines Inc. is classified in the Software - Application industry within the Technology sector. Other leadership on record at Petmed Express Inc includes Bruce S. Rosenbloom (CEO), Jeff Willard (CEO and Board Member), Jeffrey Allen Willard (CEO and Board Member) and 7 others.
“On behalf of Fusemachines, Inc. (the "Company"), I am very pleased to offer you the position of Chief Financial Officer.”
Fusemachines Inc. Form 8-K, filed October 29, 2025
· Read the filing
“On August 3, 2022, PetMed Express, Inc. (the “Company”) entered into an employment agreement (“Employment Agreement”) with Christine Chambers to set forth the terms and conditions of Ms. Chambers’ employment as Chief Financial Officer of the Company.”
Petmed Express Inc Form 8-K, filed August 3, 2022
· Read the filing
Christine Chambers on recent calls
“I'll now provide an update on the first quarter fiscal year 2025 results for the quarter ending June 30, 2024. Sales were $68 million compared to $78.2 million in the same period last year, a 13% decline driven by lower prescription medication sales.”
“I will now provide an update on the fourth quarter fiscal year 2024 results for the quarter ending March 31st, 2024. Fourth quarter fiscal year 2024 sales were $66.5 million compared to sales of $62.4 million in the same period last year, representing growth of 6.6% year-over-year.”
“I will now provide an update on the fourth quarter fiscal year 2024 results for the quarter ending March 31, 2024. Fourth quarter fiscal year 2024 sales were $66.5 million compared to sales of $62.4 million in the same period last year, representing growth of 6.6% year-over-year.”
“I want to first address the restatement announced in the 8-K earlier this afternoon, and then I will address selected preliminary third quarter results for fiscal year 2024.”
“Today, I will report our Q2 fiscal 2024 results for the quarter ending September 30, 2023. As a reminder, this will be the second quarter of combined results including the acquisition of PetCareRx as compared to results for PetMeds only for Q2 fiscal 2023.”
